Procarbazine, lomustine, and vincristine (PCV) regimen for central nervous system tumors

Dominic A. Solimando, James Waddell

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.

Original languageEnglish (US)
Pages (from-to)98-104
Number of pages7
JournalHospital Pharmacy
Volume52
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Lomustine
Procarbazine
Central Nervous System Neoplasms
Neurology
Vincristine
Pharmacists
Tumors
Oncology
Postal Service
Product Labeling
Off-Label Use
Pharmaceutical Services
Chemotherapy
Poisons
Highway systems
Antineoplastic Agents
Labeling
Labels
Drug Therapy
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmacology (medical)

Cite this

Procarbazine, lomustine, and vincristine (PCV) regimen for central nervous system tumors. / Solimando, Dominic A.; Waddell, James.

In: Hospital Pharmacy, Vol. 52, No. 2, 01.02.2017, p. 98-104.

Research output: Contribution to journalReview article

@article{8f813e75f3e44761b3e434ab4680d633,
title = "Procarbazine, lomustine, and vincristine (PCV) regimen for central nervous system tumors",
abstract = "The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.",
author = "Solimando, {Dominic A.} and James Waddell",
year = "2017",
month = "2",
day = "1",
doi = "10.1310/hpj5202-98",
language = "English (US)",
volume = "52",
pages = "98--104",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "2",

}

TY - JOUR

T1 - Procarbazine, lomustine, and vincristine (PCV) regimen for central nervous system tumors

AU - Solimando, Dominic A.

AU - Waddell, James

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.

AB - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.

UR - http://www.scopus.com/inward/record.url?scp=85032501467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032501467&partnerID=8YFLogxK

U2 - 10.1310/hpj5202-98

DO - 10.1310/hpj5202-98

M3 - Review article

VL - 52

SP - 98

EP - 104

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 2

ER -